Diffuse gliomas represent a heterogeneous group of universally lethal brain tumors
characterized by minimally effective genotype-targeted therapies. Recent advances have …

The identification of heterozygous neomorphic isocitrate dehydrogenase (IDH) mutations
across multiple cancer types including both solid and hematologic malignancies has …

Abstract The oncometabolite (R)-2-hydroxyglutarate (R-2-HG) produced by isocitrate
dehydrogenase (IDH) mutations promotes gliomagenesis via DNA and histone methylation …

Hotspot mutations in isocitrate dehydrogenase 1 (IDH1) and isocitrate dehydrogenase 2
(IDH2) occur in a variety of myeloid malignancies and solid tumors. Mutant IDH proteins …

Brain tumors, although rare, contribute to distinct mortality and morbidity at all ages.
Although there are few therapeutic options for brain tumors, enhanced biological …

In theory, in vitro and in vivo models for human gliomas have great potential to not only
enhance our understanding of glioma biology, but also to facilitate the development of novel …

2-Hydroxyglutarate (2-HG) is structurally similar to α-ketoglutarate (α-KG), which is an
intermediate product of the tricarboxylic acid (TCA) cycle; it can be generated by reducing …

Mutations affecting isocitrate dehydrogenase (IDH) enzymes are prevalent in glioma,
leukemia, and other cancers. Although mutant IDH inhibitors are effective against leukemia …

Glioblastoma (GBM) is the most common form of brain tumor characterized by its resistance
to conventional therapies, including temozolomide, the most widely used chemotherapeutic …

Glioblastoma ranks among the most lethal of all human cancers. Glioblastomas display
striking cellular heterogeneity, with stem-like glioblastoma stem cells (GSCs) at the apex …